Enterprise Value

195.5M

Cash

119.8M

Avg Qtr Burn

-18.48M

Short % of Float

11.42%

Insider Ownership

2.58%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ATI-1777 (JAK 1/3 inhibitor) Details
Atopic dermatitis, Skin disease/disorder

Phase 2b

Data readout

Zunsemetinib (ATI-450) (MK2 inhibitor) Details
Psoriatic arthritis

Big Mover™

Susp. Mover™

Phase 2a

Data readout

ATI-2138 (ITK/JAK3 inhibitor) Details
Autoimmune disease, Ulcerative colitis

Phase 2a

Initiation

ATI-2231 (MK2 inhibitor) Details
Solid tumor/s, Pancreatic cancer, Cancer, Metastatic breast cancer

Phase 1a

Initiation

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued